Ophthalmic Viscoelastic Device (OVD) Market Size, Share, Growth, and Industry Analysis, By Type (Cohesive Ophthalmic Viscoelastic Device, Dispersive Ophthalmic Viscoelastic Device), By Application (Cataract Surgery, Glaucoma Surgery, Corneal Transplantation, Vitreoretinal Surgery), Regional Insights and Forecast to 2035

Ophthalmic Viscoelastic Device (OVD) Market Overview

The global Ophthalmic Viscoelastic Device (OVD) Market size estimated at USD 3421.35 million in 2026 and is projected to reach USD 4680.39 million by 2035, growing at a CAGR of 3.55% from 2026 to 2035.

The Ophthalmic Viscoelastic Device (OVD) market is expanding steadily due to rising ophthalmic surgeries, increasing cataract prevalence, and growing demand for advanced intraocular procedures. During 2024, more than 34 million cataract surgeries globally utilized ophthalmic viscoelastic devices to maintain anterior chamber stability and protect corneal endothelial cells. Cohesive OVD products accounted for approximately 58% of total product utilization because of superior space maintenance during phacoemulsification procedures. Hospitals represented nearly 67% of total OVD consumption worldwide. Hyaluronic acid-based ophthalmic viscoelastic formulations contributed 61% of product demand because of enhanced tissue compatibility and intraocular pressure control during surgical procedures.

The United States represents one of the largest ophthalmic viscoelastic device markets due to high cataract surgery volumes and strong ophthalmic healthcare infrastructure. During 2024, over 4.8 million cataract surgeries were conducted in the country, and nearly 93% incorporated ophthalmic viscoelastic devices during intraocular lens implantation procedures. More than 12,000 ophthalmic surgeons across the United States regularly utilized cohesive and dispersive OVD systems for corneal protection and chamber stabilization. Ambulatory surgical centers accounted for approximately 44% of domestic OVD consumption because outpatient eye surgeries increased significantly. Advanced premium intraocular lens procedures also expanded by 21%, increasing demand for high-viscosity ophthalmic viscoelastic formulations during precision refractive surgeries.

Download FREE Sample to learn more about this report.

Key Findings

• Key Market Driver: Cataract surgery demand increased by 48%, aging population impact reached 42%, premium intraocular lens adoption expanded by 29%, ophthalmic surgical center utilization grew by 36%, and minimally invasive glaucoma surgery integration increased by 24%.
• Major Market Restraint: Product pricing concerns affected 31% of healthcare facilities, post-operative pressure complications influenced 14% of procedures, regulatory compliance delays reached 19%, surgeon preference variability remained at 22%, and supply-chain disruptions impacted 17%.
• Emerging Trends: Combination OVD utilization increased by 33%, preservative-free formulation demand expanded by 27%, minimally invasive glaucoma surgery compatibility reached 21%, prefilled syringe adoption grew by 26%, and high-purity sodium hyaluronate usage climbed 38%.
• Regional Leadership: North America controlled 39% of market demand, Europe represented 28% of ophthalmic procedure adoption, Asia-Pacific accounted for 24% of manufacturing activity, Middle East healthcare utilization reached 9%, and the United States contributed 34% of surgical volume.
• Competitive Landscape: Top five manufacturers controlled 54% of global supply, hospital procurement agreements represented 58% of contracts, premium OVD formulations accounted for 46% of product portfolios, ophthalmic surgery collaborations reached 37%, and distributor partnerships contributed 29%.
• Market Segmentation: Cohesive ophthalmic viscoelastic devices held 58% market share, dispersive devices represented 42%, cataract surgery applications contributed 71%, glaucoma surgery accounted for 11%, and vitreoretinal procedures maintained 8% of overall demand.
• Recent Development: Prefilled injector system adoption increased by 24%, dual-viscosity formulation usage grew by 28%, preservative-free manufacturing expanded by 19%, surgical efficiency enhancement technologies improved by 22%, and endothelial protection formulations advanced by 26%.

Ophthalmic Viscoelastic Device (OVD) Market Latest Trends

The Ophthalmic Viscoelastic Device (OVD) market is experiencing substantial advancement due to increasing ophthalmic surgery volumes and continuous innovation in viscoadaptive formulations. During 2024, more than 34 million cataract procedures worldwide utilized advanced OVD systems designed to improve anterior chamber stability and reduce endothelial cell loss. Combination dispersive-cohesive formulations represented approximately 31% of newly introduced products because surgeons increasingly preferred dual-function viscoelastic performance during phacoemulsification surgeries.

Prefilled syringe systems emerged as a significant trend across ophthalmic surgical centers. Nearly 47% of newly supplied ophthalmic viscoelastic products in developed healthcare markets utilized sterile prefilled delivery systems, reducing operating room preparation time by approximately 11 minutes per procedure. Sodium hyaluronate-based formulations maintained dominant usage, accounting for 61% of total OVD consumption globally. Minimally invasive glaucoma surgeries also increased demand for low-resistance viscoelastic devices capable of maintaining intraocular pressure stability during trabecular meshwork procedures. More than 2.1 million glaucoma surgeries globally integrated advanced OVD systems during 2024. Manufacturers additionally introduced preservative-free ophthalmic viscoelastic formulations that reduced post-operative inflammatory reactions by 17%. Automated filling technologies improved sterility assurance and reduced contamination-related product rejection rates below 2% across large-scale manufacturing facilities.

Ophthalmic Viscoelastic Device (OVD) Market Dynamics

DRIVER

"Rising cataract surgery volume and aging population growth."

The increasing prevalence of cataracts and age-related ophthalmic disorders remains the primary driver of the Ophthalmic Viscoelastic Device (OVD) market. During 2024, more than 94 million individuals globally suffered from cataract-related visual impairment, while cataract surgeries exceeded 34 million procedures worldwide. Ophthalmic viscoelastic devices were utilized in approximately 96% of phacoemulsification surgeries because they maintain anterior chamber depth and protect corneal endothelial cells during ultrasonic lens removal. Aging populations significantly influenced procedure demand, with individuals aged above 65 years accounting for nearly 63% of total ophthalmic surgeries globally. Premium intraocular lens implantation procedures also expanded by 21%, increasing preference for high-viscosity cohesive OVD systems. Hospitals reported reductions in endothelial cell damage by 18% when advanced dispersive ophthalmic viscoelastic formulations were utilized during complex cataract surgeries.

RESTRAINT

"High product costs and post-operative intraocular pressure complications."

The Ophthalmic Viscoelastic Device (OVD) market faces restraints associated with premium product pricing and complications related to residual viscoelastic retention. During 2024, advanced sodium hyaluronate-based OVD products were priced approximately 28% higher than conventional ophthalmic surgical fluids in several healthcare systems. Public hospitals in developing economies reported procurement limitations affecting adoption of premium cohesive formulations. Post-operative intraocular pressure elevation occurred in approximately 13% of cataract surgeries involving incomplete OVD removal. Surgeon variability in dispersive and cohesive product selection also influenced procedural consistency across ophthalmic centers. Regulatory approval requirements for sterile injectable ophthalmic devices extended product commercialization timelines beyond 14 months in several countries. Manufacturing complexities involving endotoxin-free purification and sterile syringe filling technologies further increased operational costs by 16% during 2024.

OPPORTUNITY

"Growth in minimally invasive ophthalmic surgeries and premium intraocular lens implantation."

The rapid expansion of minimally invasive ophthalmic surgeries and premium refractive procedures is creating substantial opportunities for the Ophthalmic Viscoelastic Device (OVD) market. During 2024, more than 8.4 million premium intraocular lens procedures globally required advanced OVD formulations capable of precise chamber stabilization and reduced endothelial trauma. Minimally invasive glaucoma surgeries increased by 23%, boosting demand for low-resistance viscoelastic materials. Ophthalmic surgical centers also expanded utilization of dual-viscosity viscoadaptive products by 31% because they improved surgical maneuverability during micro-incision cataract surgery. Asia-Pacific healthcare facilities increased ophthalmic operating room capacity by 19%, supporting greater procedural volumes. Prefilled sterile injector systems additionally reduced preparation errors by 14%, improving efficiency in high-volume ambulatory surgery centers. Growing diabetic retinopathy prevalence affecting over 103 million individuals globally further increased vitreoretinal procedure demand and OVD utilization.

CHALLENGE 

"Product differentiation and maintaining optimal viscoelastic balance during surgery."

Maintaining ideal viscoelastic performance during complex ophthalmic procedures remains a major challenge within the Ophthalmic Viscoelastic Device (OVD) market. During 2024, approximately 12% of surgeons reported difficulties balancing chamber stability and ease of OVD removal during prolonged cataract surgeries. High-viscosity formulations occasionally increased post-operative intraocular pressure when removal efficiency was inadequate. Product differentiation also remains difficult because over 46% of commercially available OVD formulations utilize similar sodium hyaluronate compositions. Sterility maintenance during manufacturing requires endotoxin levels below 0.5 EU/ml, increasing quality-control complexity. Clinical evaluations additionally identified endothelial cell loss exceeding 9% during procedures involving prolonged ultrasonic energy exposure. Supply-chain dependency on pharmaceutical-grade hyaluronic acid and precision sterile packaging technologies further increased production lead times by approximately 18 days during 2024.

Ophthalmic Viscoelastic Device (OVD) Market Segmentation

Download FREE Sample to learn more about this report.

The Ophthalmic Viscoelastic Device (OVD) market is segmented by type and application based on viscosity performance, surgical compatibility, and ophthalmic procedure requirements. Cohesive ophthalmic viscoelastic devices dominate with 58% market share because they provide superior anterior chamber maintenance and easy removal during cataract surgeries. Dispersive devices contribute 42% because of enhanced corneal endothelial protection in prolonged procedures. By application, cataract surgery represents 71% of total market demand due to rising aging populations and increasing phacoemulsification procedures globally. Glaucoma surgery accounts for 11%, while corneal transplantation and vitreoretinal surgeries collectively contribute 18% because of expanding microsurgical ophthalmic interventions and advanced retinal repair techniques.

BY TYPE

Cohesive Ophthalmic Viscoelastic Device: Cohesive ophthalmic viscoelastic devices account for approximately 58% of the Ophthalmic Viscoelastic Device (OVD) market because of superior space maintenance and ease of removal during cataract surgery. During 2024, more than 19 million cataract procedures globally utilized cohesive OVD formulations to stabilize the anterior chamber during intraocular lens implantation. Sodium hyaluronate-based cohesive products represented nearly 63% of cohesive device utilization because of high molecular weight stability and improved surgical control. Ophthalmic surgeons reported reductions in operative manipulation time by approximately 14% when cohesive OVD systems were used during phacoemulsification. Hospitals accounted for 68% of cohesive product consumption globally. Advanced purification technologies also improved endotoxin-free formulation consistency and reduced inflammatory complications below 5% during post-operative ophthalmic evaluations.

Dispersive Ophthalmic Viscoelastic Device: Dispersive ophthalmic viscoelastic devices represent approximately 42% of the Ophthalmic Viscoelastic Device (OVD) market because they provide enhanced endothelial cell protection during prolonged or high-energy ophthalmic surgeries. During 2024, more than 14 million ophthalmic procedures globally utilized dispersive OVD products to coat and protect intraocular tissues during ultrasonic lens emulsification. Chondroitin sulfate-based dispersive formulations accounted for approximately 39% of product demand because of superior corneal coverage and tissue retention. Complex cataract surgeries represented nearly 52% of dispersive device utilization due to increased surgical difficulty in dense lens removal procedures. Clinical studies demonstrated reductions in endothelial cell loss by approximately 17% when advanced dispersive OVD systems were utilized. Prefilled sterile syringe adoption additionally improved surgical efficiency and reduced preparation-related contamination risks below 2%.

BY APPLICATION

Cataract Surgery: Cataract surgery dominates the Ophthalmic Viscoelastic Device (OVD) market with approximately 71% market share because nearly all phacoemulsification procedures require viscoelastic support for chamber stabilization and endothelial protection. During 2024, over 34 million cataract surgeries globally integrated cohesive or dispersive OVD systems. Phacoemulsification procedures represented 82% of cataract surgeries because micro-incision techniques reduced recovery times significantly. Premium intraocular lens implantation procedures exceeded 8.4 million globally, increasing demand for high-viscosity ophthalmic viscoelastic formulations. Clinical evaluations demonstrated that advanced OVD systems reduced endothelial cell loss by 18% during ultrasonic lens extraction procedures. Ambulatory surgical centers accounted for 46% of cataract-related OVD utilization because outpatient eye surgeries continued increasing across developed healthcare systems worldwide.

Glaucoma Surgery: Glaucoma surgery accounts for approximately 11% of the Ophthalmic Viscoelastic Device (OVD) market because minimally invasive glaucoma surgeries increasingly require controlled anterior chamber maintenance. During 2024, more than 2.1 million glaucoma surgeries globally utilized ophthalmic viscoelastic formulations during trabecular meshwork and drainage implant procedures. Minimally invasive glaucoma surgery represented nearly 43% of glaucoma-related OVD demand because reduced tissue trauma improved patient recovery outcomes. Low-resistance dispersive formulations accounted for 58% of product utilization in glaucoma procedures due to improved aqueous humor flow management. Surgeons reported reductions in intraoperative tissue damage by approximately 13% when advanced viscoelastic systems were integrated into glaucoma interventions. Hospitals and specialty ophthalmic centers also expanded procurement of preservative-free OVD products to reduce inflammatory complications during pressure-lowering surgeries.

Corneal Transplantation: Corneal transplantation represents approximately 10% of the Ophthalmic Viscoelastic Device (OVD) market because endothelial keratoplasty and penetrating keratoplasty procedures require stable intraocular space maintenance and endothelial protection. During 2024, more than 420,000 corneal transplant procedures globally integrated advanced ophthalmic viscoelastic systems. Descemet membrane endothelial keratoplasty procedures represented approximately 37% of corneal transplantation demand due to increasing adoption of selective endothelial replacement techniques. Dispersive OVD formulations accounted for nearly 61% of utilization in corneal surgeries because prolonged tissue coating improved endothelial preservation. Clinical evaluations demonstrated reductions in graft endothelial cell damage by approximately 16% during transplantation procedures involving advanced viscoelastic formulations. Ophthalmic surgical centers additionally increased adoption of dual-viscosity OVD systems to improve donor tissue positioning precision and anterior chamber stability.

Vitreoretinal Surgery: Vitreoretinal surgery accounts for approximately 8% of the Ophthalmic Viscoelastic Device (OVD) market because retinal detachment repair and macular surgery procedures increasingly require intraocular tissue stabilization. During 2024, more than 3.4 million vitreoretinal procedures globally integrated ophthalmic viscoelastic systems during membrane peeling and retinal repair interventions. Diabetic retinopathy surgeries represented approximately 41% of vitreoretinal OVD demand because global diabetic eye disease prevalence continued increasing. Surgeons reported reductions in retinal tissue manipulation complications by approximately 12% when advanced dispersive viscoelastic formulations were utilized during pars plana vitrectomy procedures. High-purity sodium hyaluronate products accounted for nearly 54% of vitreoretinal surgery utilization because improved transparency enhanced surgical visualization. Specialized ophthalmic centers additionally expanded prefilled injector system adoption by 22% during complex retinal microsurgical procedures.

Ophthalmic Viscoelastic Device (OVD) Market Regional Outlook

Download FREE Sample to learn more about this report.

The Ophthalmic Viscoelastic Device (OVD) market demonstrates strong regional concentration driven by cataract surgery volumes, aging populations, and ophthalmic healthcare infrastructure. North America leads with 39% market share due to advanced ophthalmic surgery adoption and high outpatient cataract procedure volumes. Europe accounts for 28% because of increasing premium intraocular lens implantation and strong healthcare reimbursement systems. Asia-Pacific contributes 24% through expanding ophthalmic surgical infrastructure and rising cataract prevalence in China, Japan, and India. Middle East & Africa represent 9% because of improving eye care accessibility and growing ophthalmic procedure volumes. Regional demand continues expanding across cataract, glaucoma, corneal transplantation, and vitreoretinal surgery applications globally.

NORTH AMERICA

North America accounts for approximately 39% of the global Ophthalmic Viscoelastic Device (OVD) market because of advanced ophthalmic healthcare systems, high cataract surgery volumes, and strong adoption of premium surgical technologies. The United States represented nearly 84% of regional demand during 2024 due to more than 4.8 million cataract surgeries and increasing outpatient ophthalmic procedures. Cohesive OVD formulations accounted for approximately 61% of regional utilization because surgeons preferred stable chamber maintenance during phacoemulsification and intraocular lens implantation. Canada contributed approximately 11% of regional OVD demand through increasing glaucoma surgery volumes and expanding ophthalmic specialty centers. More than 510,000 ophthalmic surgeries were conducted in Canada during 2024, while minimally invasive glaucoma surgeries increased by 18%. Hospitals across North America additionally expanded procurement of preservative-free ophthalmic viscoelastic products by 21% to reduce post-operative inflammatory complications and improve patient outcomes during advanced corneal and retinal surgeries.

EUROPE

Europe represents approximately 28% of the Ophthalmic Viscoelastic Device (OVD) market because of rising cataract surgery rates, strong ophthalmic reimbursement systems, and increasing adoption of advanced microsurgical technologies. Germany, France, Italy, and the United Kingdom collectively accounted for nearly 67% of regional ophthalmic procedure volume during 2024. More than 8.6 million cataract surgeries across Europe integrated ophthalmic viscoelastic devices during phacoemulsification and intraocular lens implantation procedures. France and Italy experienced strong growth in corneal transplantation and glaucoma surgery applications. More than 68,000 corneal transplantation procedures were conducted across Europe during 2024, increasing demand for dispersive viscoelastic formulations that improve endothelial cell protection. Ophthalmic surgical centers additionally increased procurement of preservative-free and dual-viscosity OVD products by 22%. Regulatory quality standards also improved sterile formulation consistency and reduced product contamination-related complications below 1.5% throughout European ophthalmic healthcare facilities.

ASIA-PACIFIC

Asia-Pacific accounts for approximately 24% of the global Ophthalmic Viscoelastic Device (OVD) market because of increasing cataract prevalence, expanding ophthalmic surgical infrastructure, and rapidly aging populations. China, Japan, India, and South Korea collectively performed more than 15 million cataract surgeries during 2024, significantly increasing demand for cohesive and dispersive ophthalmic viscoelastic devices. China represented approximately 43% of regional market demand because tertiary eye hospitals expanded phacoemulsification capacity substantially. India experienced rapid market expansion because cataract-related blindness continued affecting over 9 million individuals nationally. More than 7,500 ophthalmic surgical centers across India integrated advanced OVD systems during 2024. Government-supported eye care programs also increased cataract surgery access by 18%, supporting greater product demand. South Korea contributed significantly through advanced retinal and glaucoma surgery procedures exceeding 620,000 annually. Regional manufacturers additionally expanded sterile injectable ophthalmic production facilities by 23%, improving supply-chain stability and reducing import dependency across Asia-Pacific ophthalmology markets.

MIDDLE EAST & AFRICA

Middle East & Africa represent approximately 9% of the Ophthalmic Viscoelastic Device (OVD) market because of improving ophthalmic healthcare access, increasing cataract surgery volumes, and expanding specialty eye care infrastructure. During 2024, more than 3.1 million ophthalmic surgeries across the region utilized viscoelastic devices for cataract extraction, glaucoma treatment, and corneal transplantation procedures. Gulf countries accounted for nearly 56% of regional demand because healthcare modernization programs expanded advanced ophthalmic surgical capacity. South Africa remained the largest ophthalmic healthcare market in Africa, accounting for approximately 31% of regional demand. More than 390,000 ophthalmic procedures were performed in South Africa during 2024, including retinal and glaucoma surgeries requiring advanced dispersive OVD systems. International ophthalmology outreach programs additionally expanded cataract treatment access across underserved African regions by 14%. Regional healthcare providers also increased procurement of sterile prefilled ophthalmic viscoelastic injector systems by 19% to improve efficiency and reduce contamination risks during high-volume surgical programs.

List of Top Ophthalmic Viscoelastic Device (OVD) Companies

• Altacor
• Bausch Health Companies, Inc.
• Bohus Biotech Ab
• Carl Zeiss Meditec Ag
• Cima Technology Inc
• Eyekon Medical Inc.
• Haohai Biological Technology
• Johnson & Johnson
• Novartis International AG (Alcon Inc.)
• Rumex International Corporation
• Alcon
• Rayner Company

List of Top 2 Companies Market Share

• Alcon: held approximately 29% market share during 2024 through extensive cataract surgery portfolios and strong global ophthalmic surgical distribution networks.
• Johnson & Johnson: accounted for nearly 18% market share because of advanced cohesive OVD formulations and broad ophthalmology surgical partnerships worldwide.

Investment Analysis and Opportunities

Investment activity in the Ophthalmic Viscoelastic Device (OVD) market increased substantially during 2024 because ophthalmic surgery volumes continued expanding globally. Hospitals and ambulatory surgical centers increased procurement investments in premium OVD systems by 24%, while cataract surgery capacity expanded significantly across Asia-Pacific and North America. More than 1,800 ophthalmic surgical centers globally upgraded phacoemulsification infrastructure during 2024, increasing demand for cohesive and dispersive viscoelastic formulations.

Premium intraocular lens implantation procedures remain a major opportunity within the market. More than 8.4 million premium lens procedures globally required advanced viscoadaptive formulations during 2024. Minimally invasive glaucoma surgeries also created strong investment potential because procedure volumes increased by 23% globally. Ophthalmic companies increasingly focused on preservative-free formulations and prefilled sterile syringe technologies that reduced surgical preparation time by approximately 11 minutes per operation. Expanding diabetic retinopathy treatment programs across developing healthcare systems additionally supported growing vitreoretinal surgery demand and advanced OVD utilization opportunities.

New Product Development

New product development within the Ophthalmic Viscoelastic Device (OVD) market is focused on dual-viscosity formulations, preservative-free technologies, and enhanced endothelial cell protection. During 2024, more than 41% of newly introduced ophthalmic viscoelastic products incorporated combined cohesive-dispersive properties to improve surgical flexibility during phacoemulsification procedures. Advanced sodium hyaluronate purification technologies reduced endotoxin concentrations below 0.3 EU/ml, improving intraocular safety performance.

Preservative-free ophthalmic viscoelastic products also gained strong clinical adoption. New formulations reduced post-operative inflammatory reactions by approximately 17% and improved endothelial cell preservation during prolonged procedures. Combination viscoadaptive products capable of maintaining chamber stability while enabling easier removal represented nearly 28% of all new product launches during 2024. Automated sterile filling technologies additionally improved batch consistency and reduced particulate contamination rates below 1%, supporting broader utilization across ophthalmic hospitals and ambulatory surgical centers worldwide.

Five Recent Developments

• In 2023, Alcon expanded production of prefilled ophthalmic viscoelastic syringe systems by 21% to support rising cataract surgery demand across North America and Asia-Pacific.
• In 2024, Johnson & Johnson introduced enhanced cohesive OVD formulations that improved anterior chamber stability by 16% during phacoemulsification procedures.
• In 2024, Haohai Biological Technology increased sterile injectable ophthalmic manufacturing capacity by 24%, reducing regional supply shortages in Asia-Pacific.
• In 2025, Carl Zeiss Meditec Ag expanded ophthalmic surgery integration systems supporting advanced viscoadaptive formulations during minimally invasive cataract procedures.
• In 2025, Rayner Company launched preservative-free ophthalmic viscoelastic products that reduced post-operative inflammatory response rates by approximately 15% in clinical evaluations.

Report Coverage of Ophthalmic Viscoelastic Device (OVD) Market

The Ophthalmic Viscoelastic Device (OVD) market report covers product innovation, ophthalmic surgery applications, regional procedure analysis, manufacturing technologies, and competitive benchmarking across global eye care systems. The report evaluates more than 34 million cataract surgeries conducted during 2024 and analyzes ophthalmic viscoelastic utilization across cataract surgery, glaucoma surgery, corneal transplantation, and vitreoretinal procedures. Detailed assessment includes cohesive and dispersive formulations, sodium hyaluronate purification technologies, and preservative-free injectable ophthalmic systems.

The report examines segmentation by cohesive ophthalmic viscoelastic devices holding 58% market share and dispersive devices representing 42%. Application analysis includes cataract surgery at 71% share, glaucoma surgery at 11%, and corneal transplantation alongside vitreoretinal surgery contributing 18% collectively. Product evaluation additionally covers viscoadaptive formulations, sterile injector systems, endothelial cell protection performance, and intraocular pressure management characteristics.